Stoke Therapeutics (NASDAQ:STOK) Director Sells 42,461 Shares

Key Points

• Stoke Therapeutics Director Edward Md Kaye sold 42,461 shares at an average price of $25.09, resulting in a total transaction value of over $1 million and a 46.36% decrease in his holdings.
• The company's stock price has seen fluctuations, recently trading at $27.31 with a market cap of $1.50 billion and positive earnings report beating estimates.
• Analysts have varying outlooks on Stoke Therapeutics, with a consensus price target of $25.57, and ratings including two Strong Buy, seven Buy, and one Sell.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 42,461 shares of Stoke Therapeutics stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $25.09, for a total value of $1,065,346.49. Following the sale, the director directly owned 49,124 shares of the company's stock, valued at $1,232,521.16. This represents a 46.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock traded up $0.50 during midday trading on Tuesday, hitting $27.31. The company's stock had a trading volume of 859,765 shares, compared to its average volume of 835,877. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 32.13 and a beta of 1.24. The company has a 50-day moving average price of $19.64 and a two-hundred day moving average price of $13.31. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $28.00.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

STOK has been the subject of a number of analyst reports. BTIG Research set a $28.00 target price on shares of Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They issued a "buy" rating and a $30.00 price target on the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of Stoke Therapeutics in a report on Saturday, September 27th. Wedbush boosted their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $25.57.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Siren L.L.C. lifted its stake in shares of Stoke Therapeutics by 12.4% in the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after buying an additional 247,347 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after buying an additional 5,084 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Stoke Therapeutics by 123.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after purchasing an additional 52,813 shares during the period. Invesco Ltd. raised its holdings in Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company's stock valued at $174,000 after acquiring an additional 14,118 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Stoke Therapeutics during the 1st quarter valued at approximately $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.